Adjuvant denosumab treatment in patients with resectable high-risk giant cell tumor of bone

Arif Akyıldız; Rashad Ismayılov; Denizcan Güven; Elvin Chalabiyev; Najmaddin Abdurrahimli; Sercan Aksoy

Makale detayları

Adjuvant denosumab treatment in patients with resectable high-risk giant cell tumor of bone

Yazarlar:

Arif Akyıldız | Rashad Ismayılov | Denizcan Güven | Elvin Chalabiyev | Najmaddin Abdurrahimli | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Ortopedi

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 3, pp.225-228

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001318186

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: Giant cell tumor of bone GCTB is an uncommon, benign, but aggressive osteolytic skeletal neoplasm of young adults. Although denosumab is frequently used in neoadjuvant treatment and metastatic unresectable disease in these patients, its role in adjuvant therapy is unclear. In this study, we evaluated the efficacy and safety of denosumab as an adjuvant therapy in patients with resectable high-risk GCTB. Methods: Patients with resectable high-risk GCTB over the age of 16 who received postoperative denosumab between January 2013 and September 2022 were included. Demographic and clinical characteristics of the patients, tumor localization, prior treatments, response to denosumab treatment, and adverse effects of the drug were analyzed retrospectively. Results: A total of 18 patients 10 women with a median age of 23 16-45 years were recruited. The median follow-up time was 7.1 4.2-8.7 years and the median denosumab treatment duration was 12 12-90 months. One 6 patient experienced a partial response, and 17 94 patients had stable disease. Grade 1 or 2 hypophosphatemia was the most frequent adverse effect 16.7, n3. No patients stopped therapy due to side effects, and no grade 3 or 4 incident were observed. Conclusion: Postoperative denosumab may also be useful in the adjuvant treatment of patients with high-risk resectable GCTB.

 Aims: Giant cell tumor of bone GCTB is an uncommon, benign, but aggressive osteolytic skeletal neoplasm of young adults. Although denosumab is frequently used in neoadjuvant treatment and metastatic unresectable disease in these patients, its role in adjuvant therapy is unclear. In this study, we evaluated the efficacy and safety of denosumab as an adjuvant therapy in patients with resectable high-risk GCTB. Methods: Patients with resectable high-risk GCTB over the age of 16 who received postoperative denosumab between January 2013 and September 2022 were included. Demographic and clinical characteristics of the patients, tumor localization, prior treatments, response to denosumab treatment, and adverse effects of the drug were analyzed retrospectively. Results: A total of 18 patients 10 women with a median age of 23 16-45 years were recruited. The median follow-up time was 7.1 4.2-8.7 years and the median denosumab treatment duration was 12 12-90 months. One 6 patient experienced a partial response, and 17 94 patients had stable disease. Grade 1 or 2 hypophosphatemia was the most frequent adverse effect 16.7, n3. No patients stopped therapy due to side effects, and no grade 3 or 4 incident were observed. Conclusion: Postoperative denosumab may also be useful in the adjuvant treatment of patients with high-risk resectable GCTB.

 Aims: Giant cell tumor of bone GCTB is an uncommon, benign, but aggressive osteolytic skeletal neoplasm of young adults. Although denosumab is frequently used in neoadjuvant treatment and metastatic unresectable disease in these patients, its role in adjuvant therapy is unclear. In this study, we evaluated the efficacy and safety of denosumab as an adjuvant therapy in patients with resectable high-risk GCTB. Methods: Patients with resectable high-risk GCTB over the age of 16 who received postoperative denosumab between January 2013 and September 2022 were included. Demographic and clinical characteristics of the patients, tumor localization, prior treatments, response to denosumab treatment, and adverse effects of the drug were analyzed retrospectively. Results: A total of 18 patients 10 women with a median age of 23 16-45 years were recruited. The median follow-up time was 7.1 4.2-8.7 years and the median denosumab treatment duration was 12 12-90 months. One 6 patient experienced a partial response, and 17 94 patients had stable disease. Grade 1 or 2 hypophosphatemia was the most frequent adverse effect 16.7, n3. No patients stopped therapy due to side effects, and no grade 3 or 4 incident were observed. Conclusion: Postoperative denosumab may also be useful in the adjuvant treatment of patients with high-risk resectable GCTB.

 Aims: Giant cell tumor of bone GCTB is an uncommon, benign, but aggressive osteolytic skeletal neoplasm of young adults. Although denosumab is frequently used in neoadjuvant treatment and metastatic unresectable disease in these patients, its role in adjuvant therapy is unclear. In this study, we evaluated the efficacy and safety of denosumab as an adjuvant therapy in patients with resectable high-risk GCTB. Methods: Patients with resectable high-risk GCTB over the age of 16 who received postoperative denosumab between January 2013 and September 2022 were included. Demographic and clinical characteristics of the patients, tumor localization, prior treatments, response to denosumab treatment, and adverse effects of the drug were analyzed retrospectively. Results: A total of 18 patients 10 women with a median age of 23 16-45 years were recruited. The median follow-up time was 7.1 4.2-8.7 years and the median denosumab treatment duration was 12 12-90 months. One 6 patient experienced a partial response, and 17 94 patients had stable disease. Grade 1 or 2 hypophosphatemia was the most frequent adverse effect 16.7, n3. No patients stopped therapy due to side effects, and no grade 3 or 4 incident were observed. Conclusion: Postoperative denosumab may also be useful in the adjuvant treatment of patients with high-risk resectable GCTB.

Makale detayları

Adjuvant denosumab treatment in patients with resectable high-risk giant cell tumor of bone

Yazarlar:

Arif Akyıldız | Rashad Ismayılov | Denizcan Güven | Elvin Chalabiyev | Najmaddin Abdurrahimli | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Ortopedi

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 3, pp.225-228

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001318186

pISSN:

2718-0115

Giant cell tumor of bone

denosumab

adjuvant drug therapy

Sayı

Makale detayları

Adjuvant denosumab treatment in patients with resectable high-risk giant cell tumor of bone

Yazarlar: Arif Akyıldız | Rashad Ismayılov | Denizcan Güven | Elvin Chalabiyev | Najmaddin Abdurrahimli | Sercan Aksoy

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Klinik Onkoloji | Ortopedi

Dergi: Anatolian Current Medical Journal Vol.6 Issue 3, pp.225-228

Belge Tipi: Makale

Yayın Tarihi: 5/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001318186

pISSN: 2718-0115

Giant cell tumor of bone

denosumab

adjuvant drug therapy

Sayı

Yazarlar:

Arif Akyıldız | Rashad Ismayılov | Denizcan Güven | Elvin Chalabiyev | Najmaddin Abdurrahimli | Sercan Aksoy

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Klinik Onkoloji | Ortopedi

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 3, pp.225-228

Belge Tipi:

Makale

Yayın Tarihi:

5/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001318186

pISSN:

2718-0115